Scientists create nano-size packets of genetic code aimed at brain cancer ‘seed’ cells

July 12, 2018
Nanoparticles releasing microRNAs (light blue) inside a human brain cancer cell.

Nanoparticles releasing microRNAs (light blue) inside a human brain cancer cell. (Credit: Yuan Rui, Johns Hopkins)

In a “proof of concept” study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice. The contents of the super-small containers were designed to target cancer stem cells, a kind of cellular “seed” that produces countless progeny and is a relentless barrier to ridding the brain of malignant cells.

Results of their experiments were published online June 21 in Nano Letters.

“Brain cancer is one of the most widely understood cancers in terms of its genetic makeup, but we have yet to develop a good treatment for it,” says John Laterra, MD, PhD, professor of neurology, oncology and neuroscience at the Johns Hopkins University School of Medicine and a research scientist at the Kennedy Krieger Institute. “The resilience of cancer stem cells and the blood-brain barrier are major hurdles.”

Blood that enters the brain is filtered through a series of vessels that act as a protective barrier. But this blood-brain barrier blocks molecular medicines that have the potential to revolutionize brain cancer therapy by targeting cancer stem cells, says Laterra.

“To modernize brain tumor treatments, we need tools and methods that bypass the blood-brain barrier,” says Jordan Green, PhD, professor of biomedical engineering, ophthalmology, oncology, neurosurgery, materials science and engineering and chemical and biomolecular engineering at the Johns Hopkins University School of Medicine. “We need technology to safely and effectively deliver sensitive genetic medicines directly to tumors without damaging normal tissue.”

A case in point, Green says, is glioblastoma, the form of brain cancer that Arizona Sen. John McCain is battling, which often requires repeated surgeries. Doctors remove the brain tumor tissue that they can see, but the malignancy often returns quickly, says Laterra. Most patients with glioblastoma live less than two years after diagnosis.

Scientists have long suspected that cancer stem cells are at the root of what drives the return and spread of glioblastoma and other cancers. These stem cells give rise to other cancer cells and, if they evade the surgeon’s knife, can lead to an entirely new tumor.

Laterra and Green, who are members of the Johns Hopkins Kimmel Cancer Center, designed a way to efficiently deliver super-tiny packets of microRNAs into established brain tumors. The microRNAs target brain cancer stem cells to halt their capacity to propagate and sustain tumor growth.

The packets are made of biodegradable plastic similar to material used for surgical sutures and that degrades over time. They are 1,000 times smaller than the width of a human hair and typical of the size and shape of natural components that cells use to communicate. When cancer cells engulf the packets, they break apart and release their microRNA “payload” specifically where the microRNAs need to take action within the cancer cells.

Encased in the nanopacket are microRNAs that specifically bind to messenger RNAs linked to two genes: HMGA1 and DNMT, which function together to regulate gene expression programs in cells.

When microRNAs bind to these messenger RNAs, they block their protein-making abilities and turn off programs that drive the cancer cells’ stemlike characteristics. Without their stemlike properties, the cancer cells are more differentiated, they lose their capacity to propagate tumors, and they may be more susceptible to radiation and drugs.

Excerpted from Johns Hopkins Medicine >>

Back to top